Botulinum Toxin in the Treatment of Raynaud's
|ClinicalTrials.gov Identifier: NCT01233999|
Recruitment Status : Completed
First Posted : November 4, 2010
Results First Posted : April 21, 2014
Last Update Posted : April 21, 2014
The investigators are studying a medical condition known as Raynaud's Phenomenon (RP). RP is a painful condition in which cold surroundings or stressful events trigger pain, a cold sensation, and in severe cases, sores and ulcers on one's fingers. The investigators think that RP results from problems with some of the components of the blood vessels, surrounding nerves, and some of the circulating messengers in the bloodstream. Although there are many different medicines that are currently used to treat RP, the investigators have not yet found a cure for severe cases of this condition. Furthermore, the investigators have found few medicines that show consistent healing of the ulcers that may be associated with RP. Some of the treatments include medicines that are used to treat high blood pressure known as calcium channel blockers. Medications that thin the blood (anticoagulants) such as aspirin have also been used to treat RP.
In this study, the investigators will investigate a new treatment for RP known as Botulinum toxin A. Botulinum toxin is a chemical that is temporarily toxic to nerves, but has been approved by the government for the treatment of several other conditions including but not limited to: excessive sweating, neck pain associated with a condition known as cervical dystonia, uncontrollable forcible closure of the eyelids known as blepharospasm, and a condition known as strabismus in which the eyes are not in alignment with one another.
This study will aim to greatly improve the quality of life and pain associated with RP. Previous studies also support the chance that Botulinum toxin will help to heal some of the ulcers associated with RP. Although there is no current standard of care, many of the patients in the study will have already failed or are unable to tolerate commonly used treatments such as lifestyle modifications, calcium channel blockers, nitroglycerin, and anticoagulants. If the patient chooses to participate in the study, he/she will be randomly assigned to receive an injection with Botulinum toxin in either the left or right hand. The other hand will be injected with saline solution. Neither the patient nor the physician or research personnel seen in follow-up will know which hand is injected with Botulinum toxin.
|Condition or disease||Intervention/treatment||Phase|
|Raynaud's Syndrome||Drug: botulinum toxin A||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Botulinum Toxin in the Treatment of Raynaud's|
|Study Start Date :||October 2010|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||March 2012|
U.S. FDA Resources
Placebo Comparator: Botox
single-drug dosage comparison cross-over study
Drug: botulinum toxin A
Botulinum toxin A will be injected into participants hand total 40units
- Mean Digital Temperature Difference From Baseline [ Time Frame: 6 weeks ]Each digit temperature was measured and recorded at baseline, and then measured and re-recorded after 3 minute intervals following a 20 second 4 degree Celsius ice bath immersion.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01233999
|United States, Georgia|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Suephy C Chen, MD||Emory University|